Circassia Pharmaceuticals Plc (CIR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The companys marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Pharmaceuticals Plc (CIR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Circassia Pharma Acquires US Rights to Two COPD Products from AstraZeneca 11
Partnerships 13
Prosonix Enters Into Research Agreement With Imperial College London 13
Licensing Agreements 14
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 14
Equity Offering 15
Circassia Pharma Raises USD433.4 Million in Private Placement of Shares 15
Circassia Pharma Completes IPO For US$335.6 Million 16
Aerocrine Completes Private Placement Of Shares For US$15 Million 17
Acquisition 18
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 18
Circassia Pharma Acquires Prosonix for USD157.6 Million 19
Circassia Pharmaceuticals Plc - Key Competitors 21
Circassia Pharmaceuticals Plc - Key Employees 22
Circassia Pharmaceuticals Plc - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Sep 27, 2018: Circassia - Interim results for the six months ended 30 June 2018 24
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 28
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 29
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 30
Corporate Communications 31
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 31
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List Of Tables


Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Circassia Pharma Acquires US Rights to Two COPD Products from AstraZeneca 11
Prosonix Enters Into Research Agreement With Imperial College London 13
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 14
Circassia Pharma Raises USD433.4 Million in Private Placement of Shares 15
Circassia Pharma Completes IPO For US$335.6 Million 16
Aerocrine Completes Private Placement Of Shares For US$15 Million 17
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 18
Circassia Pharma Acquires Prosonix for USD157.6 Million 19
Circassia Pharmaceuticals Plc, Key Competitors 21
Circassia Pharmaceuticals Plc, Key Employees 22
Circassia Pharmaceuticals Plc, Subsidiaries 23

List Of Figures


Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 9

Circassia Pharmaceuticals Plc (CIR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The companys marketed products include Niox used to assist asthma management

USD 250 View Report

CIRCASSIA PHARMACEUTICALS PLC Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

CIRCASSIA PHARMACEUTICALS PLC Company Profile is a detailed strategic and analytical report on CIRCASSIA PHARMACEUTICALS PLC. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

GW Pharmaceuticals Plc (GWPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The companys commercialized product, Sativex is a plant-derived

USD 250 View Report

GW Pharmaceuticals Plc (GWPH) - Medical Equipment - Deals and Alliances Profile

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The companys commercialized product, Sativex is a plant-derived

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available